Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 167

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 167
---
,500 Private Placement Warrants to purchase shares of NorthView Common Stock and that such private placement warrants will expire worthless if a business combination is not consummated within the completion window; and 70 •the fact that at the Closing, the Sponsor will enter into the Registration Rights Agreement with NorthView, Profusa and the Profusa shareholders, which provides for, among other things, registration rights, including, among other things, customary demand, shelf and piggy -backrights, subject to certain restrictions and customary cut -backprovisions with respect to the shares of New Profusa Common Stock or warrants to purchase shares of New Profusa Common Stock held by certain parties following the Closing. The personal and financial interests of our officers and directors may have influenced their motivation in identifying and selecting Profusa, completing the Business Combination and may influence their operation of New Profusa following the Business Combination. This risk may become more acute as the deadline for completing an initial business combination nears. The NorthView Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Transactions and in recommending to NorthView’s stockholders that they vote “FOR” the proposals presented at the Special Meeting. In considering the recommendations of the NorthView Board to vote for the proposals, its stockholders should consider these interests. Since the Sponsor, and NorthView’s executive officers and directors will not be eligible to be reimbursed for their out-of-pocket expenses if the Business Combination is not completed, a conflict of interest may arise in determining whether Profusa is appropriate for NorthView’s initial business combination in order to close the Business Combination. At the Closing of the Business Combination, our Sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out -of-pocketexpenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no cap or ceiling on the reimbursement of out -of-pocketexpenses incurred in connection with activities on our behalf. Unless NorthView consummates an initial business combination, NorthView’s officers, directors and the Sponsor will not receive reimbursement for any out -of-pocketexpenses incurred by them to the extent that such expenses exceed the amount of available proceeds not deposited in the Trust Account, and which amount as of September30, 2024 is $8.1 million. As of the date of this proxy statement/prospectus, there were reimbursable out -of-pocketexpenses of approximately $22,650 in total. These financial interests of